Federal Register / Vol. 62, No. 229 / Friday, November 28, 1997 / Notices 63359

that expended for the preceding fiscal

year. Funds received under Title I may

not be used in maintaining the required

level of expenditures;

• That the EMA has an HIV health

services planning council and has

entered into intergovernmental

agreements with any required political

subdivisions and has developed or will

develop a comprehensive plan for the

organization and delivery of health

services, in accordance with the

legislation;

• That entities within the EMA that

receive Title I funds will participate in

an established HIV community-based

continuum of care if such continuum

exists within the EMA;

• That Title I funds will not be

utilized to make payments for any item

or service to the extent that payment has

been made, or can reasonably be

expected to be made, with respect to

that item or service (1) under any State

compensation program, under an

insurance policy, or under any Federal

or State health benefits program, or (2)

by an entity that provides health

services on a prepaid basis; and

• To the maximum extent practicable,

that HIV health care and support

services provided with Title I assistance

will be provided without regard to the

ability of the individual to pay for such

services or to the current or past health

condition of the individual. Such

services will be provided in a setting

that is accessible to low-income

individuals with HIV disease, and a

program of outreach will be provided to

inform such individuals of such

services.

o That the applicant has participated,

or will agree to participate, in the

statewide coordinated statement of need

process where it has been initiated by

the State public health agency

responsible for administering grants

under part B, and ensures that the

services provided under the

comprehensive plan are consistent with

the statewide coordinated statement of

need.

General Use of Grant Funds

EMAs must use the Title I HIV

Emergency Relief grants to provide

financial assistance to public or

nonprofit entities, or private for-profit

entities if such entities are the only

available provider of quality HIV care in

the area, for the purpose of delivering or

enhancing—

o HIV-related outpatient and

ambulatory health and support services,

including case management, substance

abuse treatment and mental health

treatment, and comprehensive treatment

services, which will include treatment

education and prophylactic treatment

for opportunistic infections, for

individuals and families with HIV

disease; and

o HIV-related inpatient case

management services that prevent

unnecessary hospitalization or that

expedite discharge, as medically

appropriate, from inpatient facilities.

In order to provide health and support

services to infants, children, and women

with HIV disease, including treatment

measures to prevent the perinatal

transmission of HIV, the EMA must use

an amount of funding from the Title I

grant not less than the percentage

constituted by the ratio of the

population in the EMA of infants,

children, and women with AIDS to the

general population of AIDS-infected

individuals in the EMA.

Federal Smoke-Free Compliance

The Public Health Service strongly

encourages all grant recipients to

provide a smoke-free workplace and

promote the non-use of all tobacco

products. In addition, Public Law 103–

277, the Pro-Children Act of 1994,

prohibits smoking in certain facilities

(or, in some cases, any portion of a

facility) in which regular or routine

education, library, day care, health care

or early childhood development

services are provided to children.

Executive Order 12372

Grants awarded for the Title I HIV

Emergency Relief Grant Program are

subject to the provisions of Executive

Order 12372, as implemented under 45

CFR Part 100, which allows States the

option of setting up a system for

reviewing applications within their

States for assistance under certain

Federal programs. The application

packages made available by HRSA to the

EMAs contained a listing of States

which have chosen to set up such a

review system and provided a point of

contact in the States for the review.

(The catalog of Federal Domestic Assistance

Numbers are: Formula Grants—93.915;

Supplemental Grants—93.914.)

Dated: November 21, 1997.

Claude Earl Fox,

Acting Administrator.

[FR Doc. 97–31210 Filed 11–26–97; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Advisory Council Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Public Law 92–463), announcement is

made of the following National

Advisory bodies scheduled to meet

during the month of December, 1997.

Name: Advisory Commission on

Childhood Vaccines (ACCV).

Date and Time: December 3, 1997; 9:00

a.m.–5:00 p.m., December 4, 1997; 9:00 a.m.–

12:00 Noon

Place: Parklawn Building, Conference

Room D, 5600 Fishers Lane, Rockville,

Maryland 20857.

The meeting is open to the public.

The full Commission will meet on

Wednesday, December 3, from 9:00 a.m. to

5:00 p.m. and on Thursday, December 4,

from 9:00 a.m. to 12:00 p.m. Agenda items

will include, but not be limited to: an update

on the Vaccine Information Statements for

newly added vaccines to the National

Vaccine Injury Compensation Program

(VICP); a discussion of potential legislative

amendments to the VICP; a report on

vaccines currently in clinical trials; a

presentation on vaccine registries, and

reports from the Department of Justice, the

National Vaccine Program Office, and routine

Program reports.

Public comment will be permitted before

lunch and at the end of the Commission

meeting on December 3 and before

adjournment on December 4. Oral

presentations will be limited to 5 minutes per

public speaker. Persons interested in

providing an oral presentation should submit

a written request, along with a copy of their

presentation to: Ms. Melissa Palmer,

Principal Staff Liaison, Division of Vaccine

Injury Compensation, Bureau of Health

Professions, Health Resources and Services

Administration, Room 8A–35, 5600 Fishers

Lane, Rockville, MD 20857, Telephone (301)

443–6593. Requests should contain the name,

address, telephone number, and any business

or professional affiliation of the person

desiring to make an oral presentation. Groups

having similar interests are requested to

combine their comments and present them

through a single representative. The

allocation of time may be adjusted to

accommodate the level of expressed interest.

The Division of Vaccine Injury Compensation

will notify each presenter by mail or

telephone of their assigned presentation time.

Persons who do not file an advance request

for a presentation, but desire to make an oral

statement, may sign-up in Conference Room

D on December 3 and 4. These persons will

be allocated time as time permits.

Anyone requiring information regarding

the Commission should contact Ms. Palmer,

Division of Vaccine Injury Compensation,

Bureau of Health Professions, Health

Resources and Services Administration,

Room 8A–35, 5600 Fishers Lane, Rockville,

Maryland 20857, Telephone (301) 443–6593.
63360 Federal Register / Vol. 62, No. 229 / Friday, November 28, 1997 / Notices

Agenda items are subject to change as

priorities dictate.

Dated: November 21, 1997.

Jane M. Harrison,

Committee Management Officer, HRSA.

[FR Doc. 97–31221 Filed 11–26–97; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Human Genome Research

Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Name of Committee: National Human

Genome Research Institute Initial Review

Group, Genome Research Review

Subcommittee.

Agenda/Purpose: To review and evaluate

grant applications and/or contract proposals.

Date: December 11, 1997.

Time: 1:00 p.m.

Place: Via Teleconference, Building 38A,

Room 609, at the National Institutes of

Health, Bethesda, MD.

Contact Person: Rudy Pozzatti, Ph.D.,

Office of Scientific Review, National Human

Genome Research Institute, National

Institutes of Health, Building 38A, Room 604,

Bethesda, Maryland 20892, (301) 402–0838.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The

applications and/or contract proposals, and

the discussions could reveal confidential

trade secrets or commercial property such as

patentable material, and personal

information concerning individuals

associated with applications, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalogue of Federal Domestic Assistance

Program No. 93.172, Human Genome

Research.)

Dated: November 21, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31230 Filed 11–26–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Human Genome Research

Institute; Notice of Meetings

Pursuant to Section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings:

Name of Committee: National Human

Genome Research Institute, Special

Emphasis Panel ZHG1 (G1).

Agenda/Purpose: To discuss a

component of NHGRI’s five-year plan.

Date: December 2–3, 1997.

Time: 8:30 a.m.–5:00 p.m.

Place: Chevy Chase Holiday, Chevy

Chase, Maryland.

Note: Advanced registration required.

Contact Person: Elise A. Feingold,

National Human Genome Research

Institute, National Institutes of Health,

Building 38A, Room 614, Bethesda,

Maryland 20892, (301) 496–7531.

This notice is being published less

than fifteen days prior to the meeting

due to the urgent need to meet

extramural process requirements.

Name of Committee: National Human

Genome Research Institute, Special

Emphasis Panel ZHG1 (P1).

Agenda/Purpose: To consider the

design issues associated with the

development of a repository of cell lines

that can be used in the discovery of

single nucleotide polymorphisms in

human DNA.

Date: December 8–9, 1997.

Time: 8:30 a.m.–5:00 p.m.

Place: Bethesda Marriott Hotel, Pooks

Hill, Bethesda, Maryland.

Note: Advanced registration required.

Contact Person: Stephanie ReevesWalker, National Human Genome

Research Institute, National Institutes of

Health, Building 38A, Room 614,

Bethesda, Maryland 20892, (301) 496–

7531.

Meeting Contact Person: Bettie

Graham, National Human Genome

Research Institute, National Institutes of

Health, Building 38A, Room 614,

Bethesda, Maryland 20892, (301) 496–

7531.

Individuals who plan to attend these

meetings and need special assistance,

such as sign language interpretation or

other reasonable accommodations,

should contact Elise Feingold or

Stephanie Reeves-Walker, (301) 496–

7531, two weeks in advance of the

meeting.

(Catalogue of Federal Domestic Assistance

Program No. 93.172, Human Genome

Research.)

Dated: November 19, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31231 Filed 11–26–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institutes of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Child Health and

Human Development Special Emphasis

Panel (SEP) meeting:

Name of SEP: The Effects of Yoga on Peak

Flow Rates in Pregnant Asthmatics

(Teleconference).

Date: December 18, 1997.

Time: 3:30 p.m. (ET)—adjournment.

Place: 6100 Executive Boulevard, Room

5E03, Rockville, Maryland 20892.

Contact Person: Norman C. Chang, Ph.D.,

Scientific Review Administrator, NICHD,

6100 Executive Boulevard, Room 5E03,

Rockville, MD 20852, Telephone: 301–496–

1485.

Purpose/Agenda: To evaluate and review a

grant application.

This meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The

discussion of this application could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the application, the

disclosure of which would constitute a

clearly unwarranted invasion of personal

privacy.

(Catalog of Federal Domestic Assistance

Program Nos. [93.864, Population Research

and No. 93.865, Research for Mothers and

Children], National Institutes of Health, HHS)

Dated: November 21, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–31227 Filed 11–26–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Institute of Mental

Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: December 9, 1997.

Time: 2 p.m.